Decreasing Cirrhosis Risk in MASLD: Don’t Drink Alcohol! Nicole E. Rich, MD, MSCS Assistant Professor, Associate Director of the Liver…

Tirzepatide Produces NASH Resolution and  Decreases Fibrosis: Results from the SYNERGY-NASH Trial Nicole E. Rich, MD MSCS Assistant Professor, Associate…

First FDA-Approved NASH Treatment Produces NASH Resolution and Decreases Fibrosis: Results From the Landmark Phase 3 MAESTRO-NASH Trial Phillip Leff,…

How Effective are Obesity Medications for Reducing Hepatic Decompensation in MASH? Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief (Emeritus), Gastroenterology…

Drs Ashwini Arvind and Nicole E. Rich look at the decade-long, NIH-funded HEDS study for incidence and risk factors for hepatocellular carcinoma in cirrhosis.

Hepatitis C Virus Testing and Treatment: A Call to Action Sonali Paul, MD, MS Assistant Professor of Medicine, Division of …

In Case You Missed It Albumin Infusions Do Not Improve Outcomes in Hospitalized Patients with Decompensated Cirrhosis: The ATTIRE Trial…

Bariatric Surgery Is Superior to Lifestyle Changes + Best Medical Care for Metabolic Dysfunction-Associated Steatohepatitis: The BRAVES Study Yichin Fu,…

Evidence-based summary of “Response-Guided Therapy with Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Validation Study of 2021 AASLD Practice Guideline for SBP,” published in the American Journal of Gastroenterology.

Prophylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with Corticosteroids Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief…